WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318174

CAS#: 22232-71-9

Description: Mazindol is discontinued (DEA controlled substance). Mazindol is a tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.

Chemical Structure

CAS# 22232-71-9

Theoretical Analysis

MedKoo Cat#: 318174
Name: Mazindol
CAS#: 22232-71-9
Chemical Formula: C16H13ClN2O
Exact Mass: 284.07164
Molecular Weight: 284.74
Elemental Analysis: C, 67.49; H, 4.60; Cl, 12.45; N, 9.84; O, 5.62

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Mazindol; Mazanor; Sanorex; Teronac; Dimagrir; Magrilon; Solucaps; Teronac; Teronak; Wyeth Brand of Mazindol;

IUPAC/Chemical Name: 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol


InChi Code: InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2

SMILES Code: C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 284.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: de Oliveira MH, Ferreira PC, Carlos G, Salazar FR, Bergold AM, Pechansky F,
Limberger RP, Fröehlich PE. Validation and application of a liquid
chromatography-electrospray ionization mass spectrometric method for
determination of mazindol in human plasma and urine. J Pharmacol Toxicol Methods.
2015 Dec 21;79:1-6. doi: 10.1016/j.vascn.2015.12.003. [Epub ahead of print]
PubMed PMID: 26718151.

2: de Oliveira MH, Carlos G, Bergold AM, Pechansky F, Limberger RP, Fröehlich PE.
Determination of mazindol in human oral fluid by high performance liquid
chromatography-electrospray ionization mass spectrometry. Biomed Chromatogr. 2014
Aug;28(8):1064-9. doi: 10.1002/bmc.3120. Epub 2014 Jan 23. PubMed PMID: 24458547.

3: Rygula R, Szczech E, Papciak J, Nikiforuk A, Popik P. The effects of cocaine
and mazindol on the cognitive judgement bias of rats in the ambiguous-cue
interpretation paradigm. Behav Brain Res. 2014 Aug 15;270:206-12. doi:
10.1016/j.bbr.2014.05.026. Epub 2014 May 23. PubMed PMID: 24859175.

4: Gonçalves CL, Scaini G, Rezin GT, Jeremias IC, Bez GD, Daufenbach JF, Gomes
LM, Ferreira GK, Zugno AI, Streck EL. Effects of acute administration of mazindol
on brain energy metabolism in adult mice. Acta Neuropsychiatr. 2014
Jun;26(3):146-54. doi: 10.1017/neu.2013.43. PubMed PMID: 25142190.

5: Sakayori T, Tateno A, Arakawa R, Ikeda Y, Suzuki H, Okubo Y. Effect of
mazindol on extracellular dopamine concentration in human brain measured by PET.
Psychopharmacology (Berl). 2014 Jun;231(11):2321-5. doi:
10.1007/s00213-013-3392-2. Epub 2014 Jan 8. PubMed PMID: 24398821.

6: Severinsen K, Koldsø H, Thorup KA, Schjøth-Eskesen C, Møller PT, Wiborg O,
Jensen HH, Sinning S, Schiøtt B. Binding of mazindol and analogs to the human
serotonin and dopamine transporters. Mol Pharmacol. 2014 Feb;85(2):208-17. doi:
10.1124/mol.113.088922. Epub 2013 Nov 8. PubMed PMID: 24214825.

7: Konofal E, Zhao W, Laouénan C, Lecendreux M, Kaguelidou F, Benadjaoud L,
Mentré F, Jacqz-Aigrain E. Pilot Phase II study of mazindol in children with
attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014 Dec
1;8:2321-32. doi: 10.2147/DDDT.S65495. eCollection 2014. PubMed PMID: 25525331;
PubMed Central PMCID: PMC4266272.

8: Nittur N, Konofal E, Dauvilliers Y, Franco P, Leu-Semenescu S, Cock VC,
Inocente CO, Bayard S, Scholtz S, Lecendreux M, Arnulf I. Mazindol in narcolepsy
and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term
chart review. Sleep Med. 2013 Jan;14(1):30-6. doi: 10.1016/j.sleep.2012.07.008.
Epub 2012 Oct 1. PubMed PMID: 23036267.

9: Mori Y. [Mazindol]. Nihon Rinsho. 2011 Jan;69 Suppl 1:683-6. Review. Japanese.
PubMed PMID: 21766681.

10: Nikiforuk A, Gołembiowska K, Popik P. Mazindol attenuates ketamine-induced
cognitive deficit in the attentional set shifting task in rats. Eur
Neuropsychopharmacol. 2010 Jan;20(1):37-48. doi: 10.1016/j.euroneuro.2009.08.001.
Epub . PubMed PMID: 19729284.

11: Kim SS, Lee HW, Lee KT. Validated method for determination of mazindol in
human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B
Analyt Technol Biomed Life Sci. 2009 Apr 1;877(10):1011-6. doi:
10.1016/j.jchromb.2009.02.049. Epub 2009 Feb 27. PubMed PMID: 19272843.

12: Wellman PJ. Systemic mazindol reduces food intake in rats via suppression of
meal size and meal number. J Psychopharmacol. 2008 Jul;22(5):532-5. doi:
10.1177/0269881107083837. Epub 2008 Jan 21. PubMed PMID: 18208906.

13: Shimizu H, Tsuchiya T, Oh-I S, Ohtani K, Okada S, Mori M. Incidence of
β3-adrenergic receptor polymorphism and prediction of successful weight reduction
with mazindol therapy in severely obese Japanese subjects. Obes Res Clin Pract.
2007 May;1(2):I-II. doi: 10.1016/j.orcp.2007.02.002. PubMed PMID: 24351452.

14: Feng J, Pan Z, Cao H, Wang C. [Determination of fenfluramine, diethylpropion
and mazindol in slimming foods by gas chromatography-mass spectrometry]. Se Pu.
2004 May;22(3):228-30. Chinese. PubMed PMID: 15712903.

15: Raffel DM, Chen W. Binding of [3H]mazindol to cardiac norepinephrine
transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch
Pharmacol. 2004 Jul;370(1):9-16. Epub 2004 Jul 22. PubMed PMID: 15300361.

16: Enyedy IJ, Wang J, Zaman WA, Johnson KM, Wang S. Discovery of substituted
3,4-diphenyl-thiazoles as a novel class of monoamine transporter inhibitors
through 3-D pharmacophore search using a new pharmacophore model derived from
mazindol. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1775-8. PubMed PMID: 12067559.

17: Sadatomo T, Sakoda K, Yamanaka M, Kutsuna M, Kurisu K. Mazindol
administration improved hyperphagia after surgery for craniopharyngioma--case
report. Neurol Med Chir (Tokyo). 2001 Apr;41(4):210-2. PubMed PMID: 11381681.

18: Gallagher IM, Clow A, Jenner P, Glover V. Long-term effects of pergolide and
(-)-deprenyl on 3H-mazindol and 3H-spiperone binding in rat brain. Neurobiol
Aging. 1999 Nov-Dec;20(6):709-13. PubMed PMID: 10674438.

19: Gevaerd MS, Takahashi RN. Involvement of dopamine receptors on locomotor
stimulation and sensitization elicited by the interaction of ethanol and mazindol
in mice. Pharmacol Biochem Behav. 1999 Jul;63(3):395-9. PubMed PMID: 10418779.

20: Dembiec-Cohen D. Mazindol, nomifensine and desmethylimipramine inhibit
potassium-induced release of dopamine: effect of stimulus strength. J Neural
Transm (Vienna). 1998;105(6-7):735-47. PubMed PMID: 9826115.